Skip to main content
. 2022 Sep 6;27(18):5755. doi: 10.3390/molecules27185755

Figure 1.

Figure 1

ANXA5 reduces intestinal lesions after TBI. (A) Representative images of ileal HE staining (×200 magnification) at 0.5, 1, 2, and 7 days after TBI (scale bar = 40 µm). (B) Chiu’s scores of the intestinal mucosa. Intestinal injury peaked on day 2 after TBI and then declined (n = 6 mice/group). (C) Compared with TBI group, the weight of mice in ANXA 5 treatment group increased faster, and the body weight increased significantly on day 5 post-injury. (n = 10 mice/group). * p < 0.05 vs. sham group; # p < 0.05 vs. TBI group (repeated measures analysis of variance followed by Bonferroni’s post hoc test). (D,E) Representative immunofluorescence images of TUNEL staining in ileum tissue (scale bar = 100 μm). The average number of TUNEL-positive cells (in green) per ×200 field was quantified. ANXA5 treatment significantly reduced apoptotic cells compared to the TBI group (n = 6 mice/group). (F–I) Immunoblotting showed that intestinal caspase-3 and Bax increased significantly after TBI but decreased significantly after ANXA5 treatment on day 2 after TBI. Conversely, Bcl2 decreased significantly after TBI, and ANXA5 treatment could reverse this trend (n = 6 mice/group). Data are expressed as mean ± SD. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.